Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Top navigation

  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • Country List
SEARCH
Home

Main navigation

  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  1. Home
  2. INCA033989
  • SEARCH
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • Press Releases
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • Compliance & Transparency
  • Contact Us
    • Our Locations
    • Medical Information
  • United States

INCYTE AROUND THE WORLD

GLOBAL HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Submitted by jordyn on Wed, 05/10/2023 - 21:07

INCA033989

MPNs and GVHD

Myelofibrosis or ET with CALR mutation | ± ruxolitinib

mutCALR
Clinical Proof of Concept
8
Immunology
Oncology-Hematology
Footer Logo © 2012-2025 Incyte.
  • LinkedIn Icon
  • Twitter Icon
  • Instagram Icon
  • Facebook Icon
  • Youtube Icon
  • Legal Notice
  • Suppliers
  • Site Map
  • Privacy Policy
  • Cookie Policy
  • Consumer Health Data Privacy Policy